Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Controlled, Double-blind, Double-dummy, Clinical Trial Comparing Sacubitril-Valsartan Versus Valsartan in Asymptomatic, Stage A/B HFpEF Patients With Elevated Natriuretic Peptide and Abnormal LAVI. (Previously NCT02682719)

NCT04687111 is registered in ClinicalTrials.gov with Mark Ledwidge as lead sponsor.

NCT NCT04687111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04687111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Controlled, Double-blind, Double-dummy, Clinical Trial Comparing Sacubitril-Valsartan Versus Valsartan in Asymptomatic, Stage A/B HFpEF Patients With Elevated Natriuretic Peptide and Abnormal LAVI. (Previously NCT02682719)
Lead sponsor
Mark Ledwidge
Phase
Phase 2
Overall status
Unknown status
Start date
December 16, 2015
Completion date
June 11, 2021
Enrollment
250 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atrial arrhythmia, atrial remodeling, cardiovascular morbidity, fibrosis myocardial, hypertension, inflammatory myopathy, left ventricular diastolic dysfunction, left ventricular remodeling, myocardial dysfunction